Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC By Ogkologos - March 17, 2025 213 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Teacher Is Glad She Asked for More Testing After Mammogram Failed... October 28, 2020 Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint... December 9, 2020 Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic... July 2, 2021 Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with... May 15, 2024 Load more HOT NEWS For Cancer Screening, COVID-19 Pandemic Creates Obstacles, Opportunities Wishes for a New Year! Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs... Boy Asks Mom Fighting Cancer To Take Off Her Turban So...
